Recombinant Human NAV1 Protein，His

NAV1 (Nav1.7) is a voltage-gated sodium channel crucial for pain sensation, specifically in the peripheral nervous system. Its role in transmitting pain signals makes it a significant target for pain management therapies. Genetic studies have revealed that mutations in the SCN9A gene, which encodes NAV1.7, are linked to various pain disorders; for instance, gain-of-function mutations can lead to conditions such as primary erythermalgia, characterized by severe pain in the hands and feet, while loss-of-function mutations are associated with congenital insensitivity to pain. Understanding the structure and function of NAV1.7 is paramount for developing new analgesics, especially given the limitations of current pain relief medications. Research has focused on the development of NAV1.7 recombinant proteins to elucidate its intricate mechanisms and interactions with other cellular components. These studies often involve techniques such as electrophysiology and molecular biology to investigate channel activity, pharmacology, and the effects of mutations. The ability to produce NAV1.7 in a recombinant form has opened avenues for high-throughput screening of novel pain therapeutics and has fostered insights into channel structure, aiding in the design of selective inhibitors that could alleviate pain without the adverse effects associated with conventional drugs. However, challenges remain in achieving stable expression and functional activity of the recombinant protein, necessitating ongoing research in this promising field. As the understanding of NAV1.7 deepens, it is anticipated that targeted therapies can be developed, offering more effective pain relief strategies for patients suffering from chronic pain conditions.